diclazuril
النصوص أدناه منقولة حرفياً وبلغتها الأصلية من نشرات الأدوية البيطرية المعتمدة لدى إدارة الغذاء والدواء الأمريكية (FDA) وقاعدة بيانات DailyMed.
دواعي الاستعمال (13)
Chickens (7)
Broiler Chickens
For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mitis (mivati) and E. maxima; and for increased rate of weight gain and improved feed efficiency in broiler chickens. Because diclazuril is effective against E. maxima later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with E. maxima.
Clinacox™ and Flavomycin®
Broiler Chickens
For the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mitis (mivati), and E. maxima. Because diclazuril is effective against E. maxima later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with E. maxima. For increased rate of weight gain and improved feed efficiency in broiler chickens.
Clinacox™ and BMD®
Broiler Chickens
For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunette, E. mitis (mivati), and E. maxima. Because diclazuril is effective against E. maxima later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with E. maxima.
Feed continuously as the sole ration throughout the growing period. Use as sole source of organic arsenic. Over dose or lack of drug may result in leg weakness. Not for use in hens producing eggs for human food.
Clinacox™ plus 3-Nitro®
Broiler Chickens
As an aid in the control of necrotic enteritis caused or complicated by Clostridium species or other organisms susceptible to bacitracin, for improved rate of weight gain, for improved feed efficiency and improved pigmentation.
Feed throughout growing period. Start at first signs of clinical disease; vary dosage of bacitracin based on severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist. Then reduce bacitracin to prevention level (50 grams per ton). Use as sole source of organic arsenic. Drug overdose or lack of water may result in leg weakness. Not for use in hens producing eggs for human consumption. Withdrawal 5 days before slaughter.
3-Nitro® / BMD® / Clinacox™
Broiler Chickens
For increased rate of weight gain, improved feed efficiency, and improved pigmentation.
Feed continuously as the sole ration throughout the growing period. Use as sole source of organic arsenic. Over dose or lack of drug may result in leg weakness. Not for use in hens producing eggs for human food.
Clinacox™ plus 3-Nitro®
Broiler Chicken
For the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mitis (mivati), and E. maxima. Because diclazuril is effective against E. maxima later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with E. maxima. For increased rate of weight gain and improved feed efficiency in broiler chickens.
Feed continuously as the sole ration. Do not use in hens producing eggs for human food.
Clinacox™ / Stafac®
Broiler chickens
For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mitis (mivati) and E. maxima; and for prevention of necrotic enteritis caused by Clostridium perfringens susceptible to virginiamycin in broiler chickens. Because diclazuril is effective against E. maxima later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with E. maxima.
Clinacox® and Stafac®
Turkeys (3)
Growing Turkeys
For the prevention of coccidiosis caused by Eimeria adenoeides, E. gallopavonis, and E. meleagrimitis, and for increased rate of weight gain and improved feed efficiency in growing turkeys.
Clinacox™ and Flavomycin®
Growing Turkeys
For the prevention of coccidiosis caused by Eimeria adenoeides, E. gallopavonis, and E. meleagrimitis, and for improved feed efficiency in growing turkeys.
Clinacox™ and Flavomycin®
Growing Turkeys
For the prevention of coccidiosis caused by Eimeria adenoeides, E. gallopavonis and E. meleagrimitis.
Clinacox™ 0.2%
Horses (1)
For the treatment of equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona.
For oral use in horses only. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Protazil®
دون تحديد نوع الحيوان (2)
Broiler chickens: For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mitis (mivati) and E. maxima. Because diclazuril is effective against E. maxima later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with E. maxima. Growing Turkeys: For the prevention of coccidiosis caused by Eimeria adenoeides, E. gallopavonis and E. meleagrimitis. IMPORTANT: MUST BE THOROUGHLY MIXED INTO POULTRY FEEDS BEFORE USE.
FDA application 140-951
PROTAZIL® (1.56% diclazuril) Antiprotozoal Pellets are indicated for the treatment of equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona in horses.
PROTAZIL® (1.56% diclazuril) ANTIPROTOZOAL PELLETS
آلية العمل (1)
دون تحديد نوع الحيوان (1)
The effectiveness of diclazuril in inhibiting merozoite production of Sarcocystis neurona and S. falcatula in bovine turbinate cell cultures was studied by Lindsay and Dubey (2000).1 Diclazuril inhibited merozoite production by more than 80% in cultures of S. neurona or S. falcatula treated with 0.1 ng/mL diclazuril and greater than 95% inhibition of merozoite production (IC95) was observed when infected cultures were treated with 1.0 ng/mL diclazuril. The clinical relevance of the in vitro cell culture data has not been determined.
PROTAZIL® (1.56% diclazuril) ANTIPROTOZOAL PELLETS
موانع الاستعمال (1)
دون تحديد نوع الحيوان (1)
Use of PROTAZIL® (1.56% diclazuril) Antiprotozoal Pellets is contraindicated in horses with known hypersensitivity to diclazuril.
PROTAZIL® (1.56% diclazuril) ANTIPROTOZOAL PELLETS
التحذيرات (1)
دون تحديد نوع الحيوان (1)
For use in horses only. Do not use in horses intended for human consumption. Not for human use. Keep out of reach of children.
PROTAZIL® (1.56% diclazuril) ANTIPROTOZOAL PELLETS
الآثار الجانبية (1)
دون تحديد نوع الحيوان (1)
There were no adverse effects noted in the field study which could be ascribed to diclazuril.
PROTAZIL® (1.56% diclazuril) ANTIPROTOZOAL PELLETS
الجرعات (13)
Chickens (8)
Broiler Chickens
Diclazuril 0.91 grams per ton feed in combination with bacitracin methylene disalicylate 100 to 200 grams per ton of feed plus roxarsone 22.7 to 45.4 grams per ton.
Oral
Feed throughout growing period. Start at first signs of clinical disease; vary dosage of bacitracin based on severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist. Then reduce bacitracin to prevention level (50 grams per ton). Use as sole source of organic arsenic. Drug overdose or lack of water may result in leg weakness. Not for use in hens producing eggs for human consumption. Withdrawal 5 days before slaughter.
3-Nitro® / BMD® / Clinacox™
Broiler Chickens
Diclazuril 0.91 grams per ton of feed in combination with bambermycins 1 to 2 grams per ton of feed.
Oral
Clinacox™ and Flavomycin®
Broiler Chickens
0.91 grams diclazuril per ton (1 part per million) with 22.7 to 45.4 grams per ton roxarsone.
Oral
Feed continuously as the sole ration throughout the growing period. Use as sole source of organic arsenic. Over dose or lack of drug may result in leg weakness. Not for use in hens producing eggs for human food.
Clinacox™ plus 3-Nitro®
Broiler Chickens
Diclazuril: 0.91 g/ton (1 ppm) Bacitracin methylene disalicylate: 4 to 50 g/ton
Oral
Clinacox™ and BMD®
Broiler Chickens
Diclazuril: 0.91 g/ton (1 ppm) Virginiamycin: 5 to 15 g/ton
Oral
Feed continuously as the sole ration. Do not use in hens producing eggs for human food.
Clinacox™ / Stafac®
Broiler Chickens
0.91 grams per ton (1 part per million). Feed continuously.
Oral
Clinacox™ 0.2%
Broiler Chicken
Diclazuril: 0.91 g/ton (1 ppm) Virginiamycin: 5 g/ton
Oral
Feed continuously as the sole ration. Do not use in hens producing eggs for human food.
Clinacox™ / Stafac®
Broiler chickens
0.91 grams (1 ppm) diclazuril and 20 grams virginiamycin per ton of Type C medicated feed.Feed as the sole ration.
Oral
Clinacox® and Stafac®
Turkeys (3)
Growing Turkeys
Diclazuril: 0.91 g/ton (1 ppm) Bacitracin Methylene Disalicylate: 4 to 50 g/ton
Oral
Clinacox™ and BMD®
Growing Turkeys
0.91 grams per ton (1 part per million). Feed continuously as the sole ration.
Oral
Clinacox™ 0.2%
Growing Turkeys
Diclazuril: 0.91 g/ton (1 ppm) Bambermycins: 1 to 2 g/ton
Oral
Clinacox™ and Flavomycin®
Horses (1)
Administer as a top dress in the daily grain ration at a rate of 1 milligram per kilogram (0.45 milligrams per pound) of body weight for 28 days. The quantity necessary to deliver this dose is 64 mg pellets per kg (29 mg pellets/lb) of body weight.
Oral
For oral use in horses only. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Protazil®
دون تحديد نوع الحيوان (1)
To manufacture a Type C medicated feed directly from the Type A medicated article: Thoroughly mix one pound (1 lb) of CLINACOX (0.2% diclazuril) into each ton of complete feed to provide 0.91 g/ton (1 ppm) of diclazuril (use level). It is recommended that an intermediate mix containing one part CLINACOX and not less than nine parts appropriate feed ingredient be thoroughly mixed before incorporation into the final feed. To manufacture a Type B medicated feed and then a Type C medicated feed: Thoroughly mix 200 lbs of CLINACOX (0.2% diclazuril) with 1800 lbs unmedicated feed to produce 2000 lbs of Type B medicated feed containing 182 g/ton (200 ppm) diclazuril. Thoroughly mix 10 lbs of the resulting Type B medicated feed with 1990 lbs of unmedicated feed to produce 2000 lbs of Type C medicated feed containing 0.91 g/ton (1 ppm) diclazuril. The resulting Type C medicated feed should be fed continuously as the sole ration. CAUTION: Do not feed to breeding turkeys. WITHDRAWAL PERIODS AND RESIDUE WARNINGS No withdrawal period is required when used according to labeling. Do not feed to birds producing eggs for human consumption.
ORAL
FDA application 140-951
التراكيز المتوفرة (13)
| المنتج | الشكل الصيدلاني | التراكيز المتوفرة |
|---|---|---|
| Protazil® | Pellet | Each 100 grams of pellets contain 1.56 grams diclazuril. |
| Clinacox™ plus 3-Nitro® | Type C Liquid Medicated Feed | Diclazuril: 0.2 percent activity Roxarsone: 10, 20, 50, and 80 percent activity |
| 3-Nitro® / BMD® / Clinacox™ | Medicated Feed | Diclazuril: Type A medicated article in a single concentration of 0.91 grams diclazuril activity per pound. Bacitracin methylene disalicylate: Type A medicated article in concentrations of 10, 25, 30, 40, 50, 60, or 75 grams of bacitracin activity per pound. Roxarsone: Type A medicated article in concentrations of 45.4, 90, 227, or 360 grams of roxarsone activity per pound. |
| Clinacox™ and Flavomycin® | Type A Medicated Article | Diclazuril: Type A medicated article in a single concentration of 0.2% diclazuril. Bambermycins: Type A medicated article in concentrations of 2, 4, or 10 grams of bambermycins activity per pound. |
| Clinacox™ and BMD® | Medicated Feed | Diclazuril: Type A medicated article in a single concentration of 0.2% diclazuril. Bacitracin methylene disalicylate: Type A medicated article in concentrations of 10, 25, 30, 40, 50, 60, or 75 grams of bacitracin methylene disalicylate activity per pound. |
| Clinacox™ and BMD® | Medicated Feed | Diclazuril: Type A medicated article in a concentration of 0.91 grams diclazuril activity per pound. Bacitracin methylene disalicylate: Type A medicated article in concentrations of 10, 25, 30, 50, 60, or 75 grams of bacitracin activity per pound. |
| Clinacox™ and Flavomycin® | Type A Medicated Article | Diclazuril: Type A medicated article in a concentration of 0.91 grams diclazuril activity per pound. Bambermycins: Type A medicated article in concentrations of 2, 4, or 10 grams of bambermycins activity per pound. |
| Clinacox™ / Stafac® | Medicated Feed | Diclazuril is supplied as a Type A medicated article in a concentration of 0.91 grams diclazuril activity per pound. Virginiamycin is supplied as a Type A medicated article in concentrations of 5, 10, 20, 50, or 227 grams of virginiamycin activity per pound. |
| Clinacox™ / Stafac® | Medicated Feed | Diclazuril is supplied as a Type A medicated article in a concentration of 0.91 grams diclazuril activity per pound. Virginiamycin is supplied as a Type A medicated article in concentrations of 5, 10, 20, 50, or 227 grams of virginiamycin activity per pound. |
| Clinacox™ 0.2% | Medicated Feed | Type A medicated article: 0.2 percent of diclazuril |
| Clinacox™ 0.2% | Medicated Feed | Type A medicated article: 0.2 percent of diclazuril |
| Clinacox® and Stafac® | Type A Medicated Article | Diclazuril: 0.2% diclazuril. Virginiamycin: 10, 20, 50, or 227 g/lb. virginiamycin |
| — | — | 0.9 g / 1 kg |